Search the Newsreel

AmpliTech Group (AMPG) lifts margins, raises cash and okays $10M buyback

Belite Bio (BLTE) Is Up 12.9% After FDA Priority Review For Tinlarebant In Stargardt Disease

Belite Bio (BLTE) shares increased by 12.9% following the FDA's acceptance and Priority Review designation for its New Drug Application for tinlarebant, aimed at treating Stargardt Disease Type 1. The PDUFA target action date is set for February 12, 2027, and if approved, tinlarebant …

Belite Bio (NASDAQ:BLTE) Stock Price Down 7.2% - Should You Sell?

Belite Bio (NASDAQ:BLTE) stock declined 7.2% to $166.11 on Thursday, with trading volume below its average. Despite the drop, analysts have a "Moderate Buy" consensus rating with an average price target of $204.40. The company, a clinical-stage biotechnology firm, reported a narrower-than-expected quarterly loss …

Gilat Presents Expanded Portfolio for Tactical Unmanned Platforms

Gilat Satellite Networks Ltd., through its subsidiary Gilat Defense, has expanded its product portfolio to support tactical unmanned platforms with the introduction of RaySat’s new Viper Ka Electronically Steered Antenna (ESA). The Viper ESA is designed for resilient multi-orbit connectivity across LEO, MEO, and …

Why Lumentum Holdings (LITE) Stock Is Down Today

This article first appeared on GuruFocus. Lumentum Holdings (NASDAQ:LITE) shares jumped about 14% on Wednesday after fiscal fourth-quarter results and the company's outlook drew positive reactions from analysts. The stock had been volatile ahead of the report, while the latest figures pointed to continued …

Belite Bio (NASDAQ:BLTE) Posts Quarterly Earnings Results, Beats Estimates By $0.19 EPS

Understand How Coherent and Lumentum Bypass an AI Bottleneck With Optics

Quick Read Coherent (COHR) posted 34% revenue growth and Lumentum (LITE) surged 109% as AI clusters abandon copper wiring in favor of optical connectivity. Coherent anchors its full photonic stack to an NVIDIA (NVDA) partnership, while Lumentum owns the high-margin laser engine inside modules …

Lumentum Holdings Inc. Stock 12‑Month Price Target Raised to $1140.51, Implies 39% Upside

Lumentum Holdings Inc.'s average price target has increased to $1140.51 from $1122.3, according to estimates from 24 analysts, with forecasts ranging from $820 to $1400 per share. This updated target suggests a 39% potential upside based on the Aug. 11 closing price. The consensus …

Lumentum Stock Jumped 14% on a Blowout Quarter. The Street’s Targets Are Still Playing Catch-Up.

Lumentum (LITE) stock surged 14% after reporting fiscal Q4 revenue and EPS that significantly beat Wall Street estimates, driven by strong demand for optical components in AI data centers. The company also provided optimistic Q1 guidance, surpassing its own long-term targets ahead of schedule. …

Belite Bio Q2 Net Loss Widens; FDA Sets PDUFA Date For Tinlarebant In February 2027

(RTTNews) - Belite Bio, Inc (BLTE), a clinical-stage drug development company, announced its financial results for the second quarter, reflecting a wider net loss. The company also provided an update on its New Drug Application (NDA) for tinlarebant for the treatment of Stargardt disease …

Belite Bio (NASDAQ: BLTE) wins FDA Priority Review and reports wider Q2 2026 loss

Belite Bio announced that the FDA accepted its New Drug Application for tinlarebant with Priority Review for treating Stargardt disease type 1, setting a PDUFA target action date of February 12, 2027. Despite this regulatory progress, the company reported a wider net loss of …

Lumentum (LITE.US) shares surge post-earnings; Wall Street analysts advise to “stay in the light”

Lumentum Stock And Other Large Cap Names Riding The AI Earnings Trade

Belite Bio Reports Unaudited Second Quarter 2026 Financial Results and Provides a Corporate Update

Belite Bio, Inc U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) with Priority Review for tinlarebant for the treatment of Stargardt disease type 1 (STGD1); Prescription Drug User Fee Act (PDUFA) target action date of February 12, 2027 Company presented …

Lumentum and AXT Ripped Higher. Investors Looking for Broad Optics Exposure Should Consider This Brand-New ETF

Lumentum and AXT saw significant stock gains after Lumentum's Q4 revenue exceeded $1 billion and provided strong guidance, driven by increasing demand for optical links in data centers. For investors seeking broad exposure to the optics sector, the newly launched Roundhill Photonics & Optics …

Lumentum’s 24.7% week restores a trend cushion, but participation is still only average

LITE closed at $890.20 after its strongest recent week, sitting 19.6% above its weekly Trend Line, while negative activity pressure and 0.9x volume keep the setup balanced rather than fully confirmed.

AmpliTech Group Cuts Titan Asset Deal to $7M; Sets $2M Cash-and-Stock Payout on 5G ORAN Transfer

AmpliTech Group has amended its asset purchase agreement with Titan Crest, reducing the total purchase price for 5G ORAN radio technology from $8 million to $7 million. This change was made due to delays in delivering product documentation. The remaining $2 million will be …

Lumentum Posts Solid Q4, Set To Hit $1.25B Revenue Target 3 Months Early

Lumentum Holdings reported a strong fiscal fourth quarter, surpassing revenue and earnings estimates. The company is set to reach its $1.25 billion revenue target three months early and now aims for $2 billion in quarterly revenue by Q4 2027, driven by accelerating demand in …

Lumentum Rockets 15% on Blowout Earnings, Coherent Climbs 9%, Corning Gains 5% on Optics Earnings and CoreWeave, Super Micro Read-Through

Quick Read LITE surged 15% after revenue more than doubled to $1.01B in fiscal Q4 2026, with CEO Michael Hurlston noting pump-laser shipments are up 80% year over year and effectively sold out. SMCI jumped 16% and CRWV soared 20% on AI infrastructure prints …

Why Lumentum Holdings Stock Is Soaring Today

This article first appeared on GuruFocus. Lumentum Holdings (NASDAQ:LITE) shares jumped about 14% on Wednesday after fiscal fourth-quarter results and the company's outlook drew positive reactions from analysts. The stock had been volatile ahead of the report, while the latest figures pointed to continued …

Lumentum Jumps 7% as AI Optics Demand Accelerates

This article first appeared on GuruFocus. Lumentum Holdings Inc. (LITE, Financials), the optical networking and photonics company, jumped about 7% after strong fiscal fourth-quarter results and an upbeat outlook reinforced expectations for continued AI infrastructure demand. Warning! GuruFocus has detected 4 Warning Sign with …

LITE Q4 Earnings Beat as AI Demand Drives Optical Growth Surge

Lumentum LITE reported fourth-quarter fiscal 2026 non-GAAP earnings of $3.23 per share, which rose 267% year over year and beat the Zacks Consensus Estimate by 8.03%. Revenues surged 109.3% year over year to $1.01 billion and topped the consensus mark by 1.79%. Cloud and …

Lumentum Earnings Top Estimates Amid Supply Chain Constraints

Lumentum reported fiscal Q4 earnings and revenue that topped estimates while fiscal Q1 2027 guidance came in slightly above views. Continue Reading

Lumentum's Fiscal Q4 Beat Sets Up NPO as Next Major Catalyst, Morgan Stanley Says

Lumentum (LITE) reported a fiscal Q4 beat, but investor reaction was muted until there is clearer vi PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade …

Lumentum Stock Jumps as Stellar Earnings Extend Blazing-Hot Run

The optical networking company reports better-than-expected earnings and revenue for its fiscal fourth quarter. Continue Reading

China Literature (SEHK:772) Stock Sees Revenue Climb As Profit Sinks

Earnings To Watch: AmpliTech Group Inc (AMPG) Q2 2026 -- GF Value Sees 77% Downside

AmpliTech Group Inc (AMPG) is scheduled to release its Q2 2026 earnings on August 13, 2026. While analysts forecast an average price target of $7, suggesting a 12.9% upside, GuruFocus estimates a GF Value of $1.4, indicating a potential 77.42% downside. The company's revenue …

Nebius, CoreWeave, Lumentum, Quantinuum, Super Micro, and More Stocks That Explain Today’s Market

Nebius soars as the so-called neocloud reports better-than-expected second-quarter results, while fellow neocloud company CoreWeave posts a narrower quarterly loss, sending the stock up sharply. Continue Reading

MSX US Stock Daily Observation: Lumentum FY2026 Q4 Earnings: AI Optical Interconnect Demand Doubles Revenue, Next-Quarter Guidance Beats Expectations Again

Belite Bio stock price target raised to $214 by H.C. Wainwright on FDA review

H.C. Wainwright has increased its price target for Belite Bio (NASDAQ:BLTE) to $214 from $200, maintaining a Buy rating, after the FDA granted Priority Review to the New Drug Application for tinlarebant, a treatment for Stargardt disease type 1. The drug, which has shown …

AMD, Lumentum, others added to GF Securities preferred list, as AI rebound to continue (AMD:NASDAQ)

GF Securities has added AMD, Lumentum, and Hon Hai to its preferred list, anticipating a continued rebound in artificial intelligence-linked stocks. The firm believes that July's difficult market conditions for the Nasdaq were a temporary setback for the AI sector. This move signals confidence …

Lumentum, CoreWeave, SMCI, and More Stocks That Explain Today’s Market

Stock futures are rising after a solid batch of tech earnings gave the broader market a boost ahead of the July inflation report. Continue Reading

Belite Bio lead asset granted FDA priority review (BLTE:NASDAQ)

The FDA has accepted Belite Bio's marketing application for its lead asset, tinlarebant, granting it priority review. This therapy targets an eye disease, and the FDA has set a target action date of February 12, 2027.

Lumentum beats quarterly forecasts as AI demand drives stronger outlook

Cloud computing applications ©Shutterstock Lumentum Holdings Inc (NASDAQ:LITE) reported fiscal fourth-quarter results above Wall Street expectations, supported by strong artificial intelligence-related demand for optical connectivity used in data centres. Adjusted earnings per share came in at $3.23, beating the analyst estimate of $2.95 by …

BofA cuts Lumentum stock price target on valuation concerns

BofA Securities has lowered its price target for Lumentum Holdings Inc. (NASDAQ:LITE) to $1,000 from $1,100, maintaining a Neutral rating due to valuation concerns despite raising earnings estimates for 2027 and 2028. The company's stock has seen a significant gain over the past year, …

What Lumentum’s Q4 Earnings Reveal About the Next Leg of the AI Optics Trade